Neurocrine Biosciences, Inc. $NBIX Shares Sold by Eagle Health Investments LP

Eagle Health Investments LP cut its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 3.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 217,200 shares of the company’s stock after selling 7,900 shares during the period. Neurocrine Biosciences accounts for 6.7% of Eagle Health Investments LP’s portfolio, making the stock its 6th largest holding. Eagle Health Investments LP owned 0.22% of Neurocrine Biosciences worth $27,300,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of the company. Geneos Wealth Management Inc. increased its position in Neurocrine Biosciences by 143.6% during the first quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock worth $25,000 after buying an additional 135 shares during the last quarter. WPG Advisers LLC acquired a new stake in shares of Neurocrine Biosciences in the first quarter valued at approximately $32,000. SVB Wealth LLC bought a new position in shares of Neurocrine Biosciences during the 1st quarter worth approximately $35,000. True Wealth Design LLC increased its holdings in shares of Neurocrine Biosciences by 1,215.4% during the 2nd quarter. True Wealth Design LLC now owns 342 shares of the company’s stock worth $43,000 after acquiring an additional 316 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd raised its stake in Neurocrine Biosciences by 6,285.7% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 447 shares of the company’s stock valued at $49,000 after acquiring an additional 440 shares during the period. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on NBIX shares. Guggenheim lifted their price objective on shares of Neurocrine Biosciences from $165.00 to $175.00 and gave the stock a “buy” rating in a research report on Friday, August 1st. JPMorgan Chase & Co. lifted their target price on shares of Neurocrine Biosciences from $171.00 to $179.00 and gave the stock an “overweight” rating in a report on Monday, November 3rd. Piper Sandler increased their price target on shares of Neurocrine Biosciences from $175.00 to $179.00 and gave the company an “overweight” rating in a report on Wednesday, October 29th. Weiss Ratings restated a “hold (c+)” rating on shares of Neurocrine Biosciences in a report on Wednesday, October 8th. Finally, Morgan Stanley lowered their target price on Neurocrine Biosciences from $178.00 to $173.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 11th. One research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $170.53.

Neurocrine Biosciences Trading Up 0.7%

Shares of NBIX opened at $138.98 on Friday. Neurocrine Biosciences, Inc. has a 12 month low of $84.23 and a 12 month high of $157.67. The firm’s 50 day moving average is $142.37 and its 200-day moving average is $133.57. The stock has a market capitalization of $13.86 billion, a PE ratio of 33.25, a P/E/G ratio of 0.94 and a beta of 0.22.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings results on Tuesday, October 28th. The company reported $2.17 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.58 by $0.59. The business had revenue of $794.90 million for the quarter, compared to the consensus estimate of $746.61 million. Neurocrine Biosciences had a return on equity of 15.82% and a net margin of 15.95%.The firm’s quarterly revenue was up 27.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.81 earnings per share. Equities research analysts predict that Neurocrine Biosciences, Inc. will post 4.28 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Neurocrine Biosciences news, Director William H. Rastetter sold 18,000 shares of the firm’s stock in a transaction dated Wednesday, November 5th. The shares were sold at an average price of $151.82, for a total value of $2,732,760.00. Following the transaction, the director directly owned 40,360 shares of the company’s stock, valued at $6,127,455.20. This trade represents a 30.84% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Kyle Gano sold 300 shares of the business’s stock in a transaction that occurred on Tuesday, November 4th. The shares were sold at an average price of $141.97, for a total transaction of $42,591.00. Following the completion of the transaction, the chief executive officer owned 140,407 shares of the company’s stock, valued at $19,933,581.79. The trade was a 0.21% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 4.80% of the stock is currently owned by company insiders.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.